TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Fiche publication
Date publication
février 2016
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Dr LIMACHER Jean-Marc, Pr WESTEEL Virginie
Tous les auteurs :
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM
Lien Pubmed
Résumé
MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemotherapy showed activity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activated lymphocytes (TrPAL) was shown to be potentially predictive of TG4010 efficacy. In this phase 2b part of the phase 2b/3 TIME trial, we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker in this setting.
Mots clés
Aged, Anemia, etiology, Antigens, CD, analysis, Antigens, CD56, analysis, Antigens, Differentiation, T-Lymphocyte, analysis, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, administration & dosage, Biomarkers, Tumor, blood, Cancer Vaccines, adverse effects, Carboplatin, administration & dosage, Carcinoma, Non-Small-Cell Lung, chemistry, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Disease-Free Survival, Double-Blind Method, Erlotinib Hydrochloride, administration & dosage, Fatigue, etiology, Female, Humans, Immunotherapy, adverse effects, Lectins, C-Type, analysis, Lung Neoplasms, chemistry, Lymphocyte Activation, Lymphocytes, chemistry, Male, Membrane Glycoproteins, adverse effects, Middle Aged, Mucin-1, analysis, Neutropenia, etiology, Paclitaxel, administration & dosage, Pemetrexed, administration & dosage, Predictive Value of Tests, Receptors, IgG, analysis
Référence
Lancet Oncol.. 2016 Feb;17(2):212-23